title: Polyamine measurements in the uterine cervix.
abstract: Cervical cancer remains a significant health problem. New strategies based on the molecular aspects of cervical carcinogenesis are needed. Chemoprevention represents a novel strategy for cervical cancer prevention. Our group plans phase I and II trials using alpha-difluoromethylornithine, a suicide inhibitor of ornithine decarboxylase and potent antiproliferative chemopreventive agent. We conducted a study to identify which polyamines in tissue could best serve as surrogate endpoint biomarkers for future trials. Thirty patients with biopsy-proven cervical intraepithelial neoplasia grade 3 underwent colposcopically directed biopsies of normal and abnormal areas of the uterine cervix for analysis of polyamine synthesis biomarkers. Statistically significant differences were found in the ornithine decarboxylase value and the spermidine:spermine ratio between normal and abnormal areas of the cervix. In general, the ranges in measurements varied widely. Differences in polyamine synthesis biomarkers between colposcopically normal and abnormal areas can be demonstrated. However, studies using polyamine synthesis biomarkers in the cervix would require large numbers of patients to achieve significance.
authors.affiliation: Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
authors.forename: M F
authors.initials: MF
authors.lastname: Mitchell
authors.forename: G
authors.initials: G
authors.lastname: Tortolero-Luna
authors.forename: J J
authors.initials: JJ
authors.lastname: Lee
authors.forename: W K
authors.initials: WK
authors.lastname: Hittelman
authors.forename: R
authors.initials: R
authors.lastname: Lotan
authors.forename: J T
authors.initials: JT
authors.lastname: Wharton
authors.forename: W K
authors.initials: WK
authors.lastname: Hong
authors.forename: K
authors.initials: K
authors.lastname: Nishioka
mesh_terms: D002584:Cervix Uteri / Q000378:metabolism*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D015331:Cohort Studies; D000518:Eflornithine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011073:Polyamines / Q000378:metabolism*; D012307:Risk Factors; D002578:Uterine Cervical Dysplasia / Q000378:metabolism / Q000517:prevention & control*
chemical_list: D011073:Polyamines; D000518:Eflornithine